फ्रेडन फार्मास्युटिकल्स शेअर किंमत

Fredun Pharmaceuticals' board has recommended a 2:1 bonus issue, granting two new equity shares for every one held. This decision aims to reward shareholders, reflecting management's confidence in the company's sustained earnings growth, scalability, and long-term value creation strategy.

• इकॉनॉमिक टाइम्स
• 4 दिवस 6 तासांपूर्वी

The board declared a dividend of 0.70 per share and approved a bonus share issue in the ratio of 2:1

• बिझनेस लाईन
• 5 दिवस 4 तासांपूर्वी

Pharmaceuticals company Fredun Pharmaceuticals announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from operations: Consolidated revenue for Q4FY26 reached Rs 21,041.20 lakh, a YoY increase of 27.18% from Rs 16,543.78 lakh in Q4FY25 and a QoQ increase of 31.57% from Rs 15,992.63 lakh in Q3FY26. Total Income: Consolidated total income for Q4FY26 was Rs 21,305.51 lakh, up 27.27% YoY from Rs 16,740.74 lakh and up 32.40% QoQ from Rs 16,092.33 lakh in Q3FY26. Profit Before Tax (PBT): Consolidated PBT for Q4FY26 was Rs 1,124.81 lakh, showing a YoY growth of 54.84% from Rs 726.44 lakh, but declining 19.67% QoQ from Rs 1,400.24 lakh in Q3FY26. Net Profit: Net profit for Q4FY26 stood at Rs 1,078.00 lakh, representing a 79.56% YoY increase from Rs 600.35 lakh and a 2.88% QoQ increase from Rs 1,047.80 lakh in Q3FY26. Full Year Performance: Consolidated revenue for FY26 was Rs 63,332.65 lakh, up 40.21% YoY from Rs 45,170.65 lakh. Annual consolidated net profit grew by 65.26% to Rs 3,262.09 lakh compared to Rs 1,973.93 lakh in FY25. Standalone Financial Highlights: Revenue from operations: For Q4FY26, the company reported revenue of Rs 21,041.20 lakh, representing a growth of 27.18% YoY from Rs 16,543.76 lakh in Q4FY25 and an increase of 31.57% QoQ from Rs 15,992.63 lakh in Q3FY26. Total Income: Total income for Q4FY26 was Rs 21,305.20 lakh, up by 27.27% YoY compared to Rs 16,740.72 lakh in Q4FY25 and a growth of 32.39% QoQ from Rs 16,092.33 lakh in Q3FY26. Profit Before Tax (PBT): PBT for Q4FY26 stood at Rs 1,153.32 lakh, marking a 43.42% increase YoY from Rs 804.17 lakh, though it saw a QoQ decline of 17.64% from Rs 1,400.25 lakh in Q3FY26. Net Profit: The company recorded a net profit of Rs 1,106.51 lakh in Q4FY26, showing a growth of 56.47% YoY from Rs 707.18 lakh in Q4FY25 and an increase of 5.60% QoQ from Rs 1,047.81 lakh in Q3FY26. Full Year Performance: For the full year FY26, revenue from operations reached Rs 63,332.65 lakh, representing a 40.21% increase from Rs 45,170.62 lakh in FY25. Net profit for the year stood at Rs 3,320.69 lakh, up by 59.59% compared to Rs 2,080.76 lakh in FY25. Earnings Per Share (EPS): Basic EPS for Q4FY26 was Rs 20.22 compared to Rs 14.98 in Q4FY25. For the full year FY26, basic EPS grew to Rs 68.01 from Rs 44.83 in FY25. Business Highlights: Dividend: The Board has recommended a final dividend of 7% (Rs 0.70 per equity share) for the financial year 2025-26, subject to shareholder approval. Bonus Issue: The Board has recommended the issuance of bonus shares in the ratio of 2:1, i.e., two bonus equity shares of face value Rs 10/- each for every one existing equity share held. The bonus shares will be issued out of securities premium, general reserves, or retained earnings as of March 31, 2026. Authorized Capital: The Board approved an increase in the company's authorized share capital from Rs 10 crore to Rs 50 crore. Segment Performance: The company's business activity falls within a single operating segment viz. "Pharmaceutical and Healthcare," hence no separate segment results are disclosed. Auditor Appointments: The company appointed M/s. Nikhil Maniar & Associates as the Internal Auditor and M/s. Joshi Apte & Associates as the Cost Auditor for the financial year 2026-27. Consolidated Entities: The consolidated results include the financial performance of three subsidiaries: Fredun Retail Private Limited, One Pet Stop Private Limited, and Wagr Retail Private Limited Result PDF

• ट्रेंडलाईन
• 5 दिवस 9 तासांपूर्वी